Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
AZD 4604 is a JAK1 inhibitor (IC50 = 0.54 nM).1 It is selective for JAK1 over JAK2 and JAK3 (IC50s = 686 and >10,000 nM, respectively), as well as tyrosine kinase 2 (TYK2; IC50 = 657 nM). AZD 4604 inhibits IL-4- or IL-13-induced phosphorylation of STAT6 in U937 cells (IC50s = 24 and 34 nM, respectively). In vivo, AZD 4604 (1 mg/kg) reduces lung STAT3 and STAT5 phosphorylation in a rat model of ovalbumin-induced asthma.2 It also inhibits lung eosinophilia and reduces the late asthmatic response in the same model.
WARNING This product is not for human or veterinary use.
1. Discovery of the potent and selective inhaled janus kinase 1 inhibitor AZD4604 and its preclinical characterization. J. Med. Chem. 66(19), 13400-13415 (2023).
2. Characterization of selective and potent JAK1 inhibitors intended for the inhaled treatment of asthma. Drug Des. Devel. Ther. 16, 2901-2917 (2022).